Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Basket Trial

Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer

10.1158/1538-7445.sabcs20-pd1-05 ◽

2021 ◽

Author(s):

Komal Jhaveri ◽

Cristina Saura ◽

Angel Guerrero-Zotano ◽

Iben Spanggaard ◽

François-Clement Bidard ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Breast Cancer Cohort ◽

Basket Trial

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Randomized Phase 2

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Annals of Oncology ◽

10.1016/j.annonc.2020.09.004 ◽

2020 ◽

Vol 31 (12) ◽

pp. 1709-1718 ◽

Cited By ~ 1

Author(s):

K. Kalinsky ◽

J.R. Diamond ◽

L.T. Vahdat ◽

S.M. Tolaney ◽

D. Juric ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Hormone Receptor ◽

Metastatic Breast ◽

Previously Treated ◽

Basket Trial

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30109-2 ◽

2017 ◽

Vol 18 (5) ◽

pp. 654-662 ◽

Cited By ~ 88

Author(s):

Hope S Rugo ◽

Lasika Seneviratne ◽

J Thaddeus Beck ◽

John A Glaspy ◽

Julio A Peguero ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Hormone Receptor Positive

Abstract OT2-01-08: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2- metastatic breast cancer

10.1158/1538-7445.sabcs16-ot2-01-08 ◽

2017 ◽

Author(s):

V Diéras ◽

E Hamilton ◽

EL Johnston ◽

T Forrester ◽

M Martín

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated

Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-ot2-01-07 ◽

2017 ◽

Cited By ~ 1

Author(s):

H Rugo ◽

S Tolaney ◽

M Dickler ◽

P Kabos ◽

C-L Ho ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3365080 ◽

2019 ◽

Author(s):

Kenji Tamura ◽

Chiyo K. Imamura ◽

Toshimi Takano ◽

Shigehira Saji ◽

Takeharu Yamanaka ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

5005 ORAL Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Comparing Tamoxifen (TAM) Plus Everolimus (RAD) With TAM Alone in Patients With Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) With Prior Exposure to Aromatase Inhibitors (Als): Implication for Research Strategies

European Journal of Cancer ◽

10.1016/s0959-8049(11)71447-2 ◽

2011 ◽

Vol 47 ◽

pp. S331 ◽

Cited By ~ 2

Author(s):

C. Bourqier ◽

I. Ray-Coquard ◽

J. Provencal ◽

C. Cropet ◽

A.V. Bourcier ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitors ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Prior Exposure ◽

Phase 2 ◽

Research Strategies ◽

Hormone Receptor Positive

Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

10.1158/1538-7445.sabcs18-p6-21-01 ◽

2019 ◽

Cited By ~ 1

Author(s):

J Crown ◽

M-P Sablin ◽

J Cortés ◽

J Bergh ◽

S-A Im ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Neutralizing Antibody ◽

Phase 2 ◽

Randomized Phase 2

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04060862 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Hormone Receptor Positive